Moran Wealth Management LLC Grows Holdings in Johnson & Johnson (NYSE:JNJ)

Moran Wealth Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 18.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,280 shares of the company's stock after buying an additional 16,115 shares during the period. Moran Wealth Management LLC's holdings in Johnson & Johnson were worth $16,796,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in JNJ. Norges Bank purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $4,390,037,000. Raymond James Financial Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth about $1,339,878,000. GAMMA Investing LLC boosted its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock worth $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.3%

NYSE JNJ traded up $0.43 on Friday, reaching $152.44. The company had a trading volume of 9,999,068 shares, compared to its average volume of 8,028,733. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a 50-day moving average of $153.85 and a 200-day moving average of $153.69. The firm has a market capitalization of $366.78 billion, a PE ratio of 16.96, a P/E/G ratio of 2.30 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is presently 57.84%.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Bank of America reduced their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Wall Street Zen upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.